Impact of BCG failure patterns on efficacy of intravesical gemcitabine/docetaxel in high‐risk non‐muscle‐invasive bladder cancer
BJU International · 2026-05 · 137 (5) · 821-828
DOI: 10.1111/bju.70182 ↗Kurz gefasst
Fachartikel in der Zeitschrift BJU International, online erschienen am 25.02.2026. Verfasst von Pietro Scilipoti und 36 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy. Hauptthemen laut MEDLINE: Deoxycytidine, Non-Muscle Invasive Bladder Neoplasms, Docetaxel, BCG Vaccine. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 17 Literaturangaben.
Abstract (Originalsprache)
Objective
To examine the impact of specific Bacillus Calmette–Guérin (BCG) failure phenotypes on treatment outcomes with intravesical gemcitabine/docetaxel in high‐risk non‐muscle‐invasive bladder cancer (HR‐NMIBC). Patients and Methods A BCG failure was classified according to the United States Food and Drug Administration (FDA)/International Bladder Cancer Group (IBCG) definitions and analysed as early refractory BCG failure, early non‐refractory BCG failure, or late BCG relapse. Kaplan–Meier methods were used to estimate recurrence‐free survival (RFS), high‐grade RFS (HG‐RFS), and progression‐free survival (PFS). Multivariable Cox proportional hazards models, adjusted for histology, multifocality, and tumour size, were used to assess the association between BCG failure patterns and oncological outcomes.
Results
Among the 143 patients included, 72 had early non‐refractory BCG failure, 36 had early refractory BCG failure, and 35 experienced late BCG relapse. The median follow‐up was 12 months. At 12 months, the RFS was 67% (95% confidence interval [CI] 55–82%) in early non‐refractory BCG failure, 54% (95% CI 36–82%) in early refractory BCG failure, and 84% (95% CI 70–100%) in late BCG relapse ( P < 0.05). Corresponding HG‐RFS rates were 75% (95% CI 64–88%), 58% (95% CI 39–87%), and 87% (95% CI 75–100%), respectively ( P < 0.05). The PFS remained >90% across all groups at 12 months. On multivariable analysis, both early non‐refractory BCG failure (adjusted hazard ratio [aHR] 3.20, 95% CI 1.31–7.82; P = 0.011) and early refractory BCG failure (aHR 3.59, 95% CI 1.28–10.1; P = 0.015) were associated with a significantly higher risk of recurrence compared with late BCG relapse, with consistent findings for HG recurrence.
Conclusions
Gemcitabine/docetaxel demonstrated meaningful activity across all BCG failure types, with late BCG relapsing patients achieving the most favourable outcomes and refractory disease showing the poorest control. These findings underscore the clinical relevance of distinguishing BCG failure subtypes when selecting candidates for post‐BCG intravesical gemcitabine/docetaxel and designing future prospective trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy.
- Vita-Salute San Raffaele University, Milan, Italy.
- Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy.
- Department of Urology UROSUD, La Croix Du Sud Hospital, Quint-Fonsegrives, France.
- Department of Urology and Oncologic Urology, Wrocław Medical University, Wroclaw, Poland.
- Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
ORCID-Profile: Pietro Scilipoti, Paolo Zaurito, Giovanni Tremolada, Ekaterina Laukhtina, Roberto Contieri, José Daniel Subiela, Renate Pichler, Tobias Klatte, Francesco Soria, David D Andrea, Maurizio Colecchia, Francesco Montorsi
Zitieren
APA
Scilipoti, P., Zaurito, P., Longoni, M., Tremolada, G., Occhi, A., Dutto, D., Katzendorn, O., Krajewski, W., Laukhtina, E., Elena, J. L. R., Aranda, J., Contieri, R., Hurle, R., Subiela, J. D., Lucena, P. E., Fernández, A., Marcq, G., Szostek, A., Pichler, R., …, & European Association of Urology – Young Academic Urologists (EAU‐YAU), Urothelial Carcinoma Working Group and the EuroGemDoce Study Group Collaborators (2026). Impact of BCG failure patterns on efficacy of intravesical gemcitabine/docetaxel in high‐risk non‐muscle‐invasive bladder cancer. BJU International, 137(5), 821-828. https://doi.org/10.1111/bju.70182
Vancouver
Scilipoti P, Zaurito P, Longoni M, Tremolada G, Occhi A, Dutto D, et al. Impact of BCG failure patterns on efficacy of intravesical gemcitabine/docetaxel in high‐risk non‐muscle‐invasive bladder cancer. BJU International. 2026;137(5):821-828. doi:10.1111/bju.70182
BibTeX
@article{Scilipoti2026,
author = {Scilipoti, Pietro and Zaurito, Paolo and Longoni, Mattia and Tremolada, Giovanni and Occhi, Angelo and Dutto, Daniele and Katzendorn, Olga and Krajewski, Wojciech and Laukhtina, Ekaterina and Elena, José Luis Rodríguez and Aranda, Javier and Contieri, Roberto and Hurle, Rodolfo and Subiela, José Daniel and Lucena, Palma Estella and Fernández, Ana and Marcq, Gautier and Szostek, Aleksandra and Pichler, Renate and Álvarez-Maestro, Mario and Bazán, Alfredo Aguilera and Klatte, Tobias and du Biest, Albane Massiet and Ferrando, Valentina and Buisan, Oscar and López, Angela Villares and Soria, Francesco and Pradere, Benjamin and D Andrea, David and Shariat, Shahrokh F and Colecchia, Maurizio and Montorsi, Francesco and Briganti, Alberto and Gontero, Paolo and Xylinas, Evanguelos and Moschini, Marco and European Association of Urology – Young Academic Urologists (EAU‐YAU), Urothelial Carcinoma Working Group and the EuroGemDoce Study Group Collaborators, European Association of Urology – Young Academic Urologists (EAU‐YAU), Urothelial Carcinoma Working Group and the EuroGemDoce Study Group Collaborators},
title = {Impact of BCG failure patterns on efficacy of intravesical gemcitabine/docetaxel in high‐risk non‐muscle‐invasive bladder cancer},
journal = {BJU International},
year = {2026},
volume = {137},
number = {5},
pages = {821--828},
doi = {10.1111/bju.70182}
}
EUVIMED